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Background: Affecting mother and child, malaria during pregnancy (MiP) provokes a double morbidity and mortality
burden. Within a package of interventions to prevent MiP in endemic areas, the WHO currently recommends intermittent
preventive treatment (IPTp). Concerns about anti-malarial resistance have however prompted interest in intermittent
screening and treating (IST) as an alternative approach to IPTp. IST involves screening for malaria infection at
scheduled antenatal care (ANC) clinic visits and treating malaria cases. In light of the need to comprehensively
evaluate new interventions prior to roll out, this article explores the acceptability of IST with artemether-lumefantrine
(AL) compared to IPTp with sulphadoxine-pyrimethamine (SP) and in Upper East Region, northern Ghana.
Methods: Data were collected alongside an open-label, randomized, controlled trial of IST-AL and IPTp-SP in Kassena-
Nankana District. Thirty pregnant women enrolled in the clinical trial participated in six focus group discussions. Ten
in-depth interviews were carried out with clinical trial staff. Observations were also made at the health facilities where
the clinical trial took place.
Results: Trial participants were generally willing to endure the discomfort of the finger prick necessary for a rapid
diagnostic test for malaria and this reflected a wider demand for diagnostic techniques. Reports of side effects were
however linked to both trial anti-malarials. Direct complaints about SP were particularly severe with regard to women’s
experience of vomiting. Although the follow-up treatment doses of AL for IST were not supervised, based on blister
inspection and questioning trial, staff were confident about participants’ adherence to the treatment course. One case
of partial adherence to the AL treatment course was reported.
Conclusion: Despite the discomfort of the finger prick required to perform the intermittent malaria screening, trial
participants generally expressed more positive sentiments towards IST-AL than IPTp-SP. Nonetheless, questions remain
about adherence to a multiple dose anti-malarial regimen during pregnancy, particularly in endemic areas where MiP
is often non-symptomatic. Any implementation of IST must be accompanied by appropriate health messages on
adherence and the necessary training for health staff regarding case management.
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Malaria during pregnancy (MiP) is a major global health
concern [1,2]. It provokes a double burden of morbidity
and mortality because it affects both mother and child, par-
ticularly in endemic regions of sub-Saharan Africa [1]. It
compounds or provokes maternal anaemia, which, when
severe, increases the risk of maternal death and it has been
estimated that, globally, malaria-related anaemia causes
around 10,000 maternal deaths each year [3]. It can also
result in low birth weight (estimated to cause around
100,000 infant deaths in Africa [3]), preterm delivery, con-
genital infection, and reproductive loss [1].
In response, the WHO recommends several interven-
tions for MiP prevention and control in areas of stable,
moderate to high malaria transmission: sleeping under
insecticide-treated bed nets (ITNs) during pregnancy (pref-
erably long-lasting insecticide-treated nets (LLINs) [4]; case
management using appropriate anti-malarial regimens [5];
and intermittent preventive treatment (IPTp) [6]. IPTp in-
volves the administration, as early as possible in the second
trimester, of treatment doses of an anti-malarial as part
of routine antenatal care (ANC). Although increasing
resistance poses questions about its continued efficacy
[7], sulphadoxine-pyrimethamine (SP) is currently used
for IPTp in many sub-Saharan African countries [8].
Coverage of IPTp-SP varies across sub-Saharan Africa
and part of this has been attributed to operational prob-
lems, including stock-outs and confusion about timing
of doses [9]. Concerns about the implications of IPTp-
SP for the prevalence of anti-malarial resistance and its
continued effectiveness [7,10] have also prompted inter-
est in a more targeted approach. Intermittent screening
and treating (IST), which involves screening women for
malaria infection using a rapid diagnostic test (RDT) at
scheduled ANC clinic visits and treatment of those who
are positive with an effective anti-malarial, has been pro-
posed as an alternative strategy for MiP prevention [11].
To date, the effectiveness of IST during pregnancy has
undergone relatively limited evaluation. The results from
a randomized, controlled, non-inferiority trial of IPTp
with SP versus IST with SP or amodiaquine + artesunate
(AQ +AS) in central Ghana suggested that this was an
effective and safe strategy for the prevention of MiP [11].
Furthermore, a qualitative study linked to this trial illus-
trated that IST was hardly noticed as an addition to the
package of ANC services provided [12]. These studies
however stressed the need to strengthen the evidence base
for IST through its comprehensive evaluation in different
malaria transmission and social contexts.
Research evaluating IPT-SP has included qualitative
studies of its acceptability across several African sites.
These studies have highlighted that in a variety of settings
SP was viewed as harmful during pregnancy [13-15].
However, in some contexts, in spite of concerns about SP,women took the IPTp-SP because of the confidence that
they placed in those delivering it [16,17]. Moreover, a
multi-site study of the social and cultural context of MiP
interventions highlighted how women generally attended
ANC and, apart from a few exceptions, adhered to IPTp-
SP as part of a general acceptance of the package of ANC
intervention, even though they disliked the side effects
that they associated with it (often vomiting) [18]. However,
the addition of the finger-prick and RDT means that this
begrudging acceptance as part of ANC cannot be extrapo-
lated to the possible implementation of IST. With the pos-
sibility of a future roll-out, it is necessary to examine how
recipients of IST react to this intervention – in terms of
their attitudes towards it and their behaviours – particu-
larly with regard to the addition of a finger-prick, RDT
and the curative anti-malarial regimen to ANC. Examin-
ing this response is not only relevant for MiP prevention
and control but also potentially for ANC attendance and
therefore mother and child health in general.
Under the auspices of the MiP Consortium [19] and as
part of a wider programme of research on the social and
cultural context of MiP [20-22], this article addresses the
question of whether IST is acceptable in a context that
is environmentally, socially, culturally and ethnically [23]
distinct from the setting of previous research on IST in
central Ghana [12]. Indeed, previous research highlight-
ing differences in attitudes and behaviours regarding mal-
aria prevention and control between pregnant women in
central and northeastern Ghana [18] emphasizes the need
conduct further research on the acceptability of IST in the
latter area. Also, the seasonal nature of malaria transmis-
sion in this area makes it a particularly relevant context
for research on the acceptability of IST; questions about
the continued effectiveness of IPTp-SP and discussions of
alternative strategies tend to focus on such malaria trans-
mission settings [24].
Therefore, to explore the acceptability of IST com-
pared to IPTp-SP in Upper East Region, northeastern
Ghana, this study describes and analyses the attitudes
and behaviours of pregnant women related to these in-
terventions when delivered as part of a clinical trial. Con-
ducting this research in the context of a clinical trial led to
a focus on the potential recipients of IST rather than those
delivering the intervention. Although this limits the scope
of the study, it is an opportunity to identify issues that can
be addressed prior to implementation.
Methods
Settings
Data were collected alongside an open-label, random-
ized, controlled trial of IST and IPTp. The clinical trial
involved recruitment of over 5,000 primigravidae and
secundigravidae during ANC visits. As part of their par-
ticipation in the study all the women were provided with
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the IST arm were screened for malaria by trained staff
using RDT and those with a positive result were treated
with artemether-lumefantrine (AL), following a three-
day regimen of two times four tablets of 20 mg artemether/
120 mg lumefantrine. The first dose was administered
at the health facility under supervision, whereas the
remaining doses were self-administered by the partici-
pants. SP-IPT involves ingestion of SP (1,500 mg sul-
phadoxine/75 mg pyrimethamine) directly observed by
ANC staff. As part of the clinical trial, participants were
encouraged to give birth in a health facility under the
supervision of trial staff and, after birth, each partici-
pant’s placenta was collected for further clinical ana-
lysis. For all trial participants, after birth, maternal
haemoglobin (via finger prick) and birth weight were re-
corded and, six weeks, post-partum, women were visited
at home and a blood sample was taken (finger prick).
The clinical trial and data collection for the acceptabil-
ity study took place Kassena-Nankana Districts, Upper
East Region, northeast Ghana. This area is part of the Sahel
and experiences an annual rainy season during which
people grow millet, maize, and vegetables for subsistence.
During the rest of the year, part of the population migrates
to other regions. The Kassena and the Nankani, make up
almost 90% of the population of the district [25]. Here,
malaria transmission is perennial but there is a seasonal
pattern with a transmission peak that coincides with the
major rains (May to October) and the low rates of infection
during the dry season [26].
Data collection
Data on the acceptability of IST and IPTp were collected
during November and December 2010, the last two months
of a year-long period of fieldwork for broader research on
the social and cultural context of MiP [18,20-22]. During
these two months, together with several field assistants
who had been extensively trained as part of the broader
research, the second author (AM) conducted six focus
group discussions (FGDs) with 30 pregnant women
participating in the clinical trial (see Table 1 for details);
ten in-depth interviews (IDIs) with staff working on the
clinical trial (midwifes, trial coordinator, field managers,
and field staff ), and made observations at the health
facilities where the clinical trial was taking place.
Trial participants were selected to ensure that women
from both arms were interviewed from a range of health
facilities (including public health centres, private clinics
and Community-based Health Planning and Service
[CHPS] posts) where the trial was conducted. The FGDs
included women from a single or both trial arms and
were undertaken in an attempt to incorporate as many
trial participants as possible in the limited time frame
for fieldwork and to elicit normative responses as well as
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responsibilities were selected for interview to ensure as
diverse as possible range of experiences and opinions were
included for analysis. Because trial staff were selected from
different levels of the hierarchy, individual interviews were
deemed most relevant to ensure that the responses of
lower level staff were not influenced by the presence of su-
periors. Across four health facilities, observations were
made of with recruitment and the daily activities of the
clinical trial, which included the finger-prick for IST (an
element of IST that has potential ramifications for its
acceptability).
FGDs and IDIs were conducted using topic guides that
focused on respondents’ experiences of the trial proce-
dures, particularly the finger pricks used as part of mal-
aria diagnosis with an RDT and the medication delivered
as part of the trial. In keeping with the anthropological
approach of the broader study, IDIs and FGDs were con-
ducted in a flexible, reflexive and iterative manner that
adapted to the topics emerging during data collection.
The interviews were conducted in Kassem, Nankani or
English and translated into English (if necessary) for
analysis. To maintain data quality and check for errors,
trained field staff conducted transcription and transla-
tion under the supervision of the field coordinator (SC)
and AM. Both SC and AM also read the transcripts
shortly after their completion and discussed their con-
tent with the translator/transcriber.
The resulting interview and focus group transcripts,
along with the field notes from observations, were ana-
lysed together using QSR NVivo 10. A codebook was de-
veloped using largely pre-established categories based on
the original research question but also modified as themes
emerged from the data. CP undertook coding and analysis
in consultation with AM.
Ethics statement
Ethical clearance was obtained from the Clinical Research
Ethics Committee, Hospital Clinic-University of Barcelona.
Additional local ethical clearance was obtained in Ghana
from the Institutional Review Board of the Navrongo
Health Research Centre, Navrongo. As approved by the
ethics review committees, informed consent was obtained
orally from study participants. With the permission of
respondent(s), interview/FGD was audio recorded (along
with the informed consent itself).
Results
From the focus groups and interviews with trial partici-
pants and staff, several key issues were identified as
particularly relevant to the acceptability of IST-AL and
IPTp-SP. These included attitudes and behaviour relating
to malaria screening with an RDT along with the
perceived side effects, efficacy and adherence of both trialdrugs. The clinical trial context also influenced how these
interventions were received.
Screening for malaria
The RDT used to diagnose malaria amongst trial
participants entailed blood samples being drawn via finger
prick. Interviewed trial participants viewed this as a pain-
ful procedure but many expressed a willingness to endure
the discomfort and discover whether they were suffering
malaria.
Respondent (R) 2: For me, I think the prick on your
hand to test is far better. When you are tested they will
know whether you have serious malaria or not. If you
have the serious one, they will know what to do.
R3: For me, I think they will have to test before the
give the medicine. If they don’t test how can they start
to give you medicine without testing you to know what
the problem is.
FGD, women in IPTp and IST arms (Central Clinic)
However, for some, the prospect of a finger prick pro-
voked sufficient fear as to prefer foregoing diagnosis
and receiving an anti-malarial regardless of a confirmed
infection.
I also prefer to take the [SP] because at times when
they are going to prick your hand they won’t warn you,
which makes it very painful. That is why I just don’t
like it.
FGD participant, women in IPTp and IST arms (Paga
Health Centre)
Health staff reported that most women were unhappy
with the finger-prick. Observations also suggested that
women found the process uncomfortable, often averting
their eyes during the procedure. Furthermore, the trial
field coordinator described how some women would be
deterred from participating in the trial because of the
finger pricks.
Some of [the women] say that they are fed up. You
know, when they come to us, we do pricking and take
blood samples, to know their HB, if they have malaria
and so many other things. Some of the women fear
pricking and so, when we invite them [to participate in
the trial] they won’t come.
IDI, trial field coordinator
The concerns were particularly related to the pain and
discomfort of the finger-prick but there had also been
complaints about a lack of compensation for the follow-
up blood testing of participants from both trial arms.
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cisms had led to trial staff providing a bar of soap as an
incentive after each finger prick conducted at all trial
participants’ homes six weeks post partum. Although
trial staff were also aware of problems with blood sam-
pling at other research sites, particularly with regard to
rumours of ‘blood stealing’, they had not encountered
such rumours, which they linked to the local popula-
tion’s familiarity with medical research, the small
quantity of blood that was sampled and the exp-
lanations that were given during the consent process
about the reasons for blood sampling. Similarly, there
was little reported resistance to the post-partum collec-
tion and sampling of the participants’ placentas: al-
though potentially divisive, women were placated by the
explanations that they received on enrolment. With re-
gard to clinical research more generally in this research
site, one trial staff member explained:
Respondent (R): When we are taking the blood we tell
them what we are going to use the samples for. We
also tell them that we are not taking much of their
blood. So at the end they know that we are using their
blood to know their HB and to see if they have
malaria but not to give it to some other people. So
they cooperate with us.
Interviewer (I): So you think that if you were taking
more blood there would be more problems?
R: Yes. If we were taking a lot of blood they may think
that we are selling it for money or that we are
donating it to some other people.
I: Has it ever happened like that in any trial here in
Navrongo?
R: No. In the projects that I know they also don’t take
much blood.
IDI, trial field coordinator
Indeed, the observations of the consent process suggest
that the trial staff were careful to spell out that trial par-
ticipation entailed malaria diagnosis via finger-prick and
use of the placenta for research. Women were also given
explanations as to why these procedures were conducted.
Trial drugs: side effects, perceived efficacy and adherence
Artemether-lumefantrine (AL)
Women’s reports regarding the efficacy of AL were mixed.
As the excerpt below indicates, the trial participants ex-
perience of the ‘yellow malaria drugs’ had varying degrees
of success in terms of treating bouts of malaria. Indeed,
respondent 1 in the same discussion explained this in
terms of everyone having a ‘different body’. There was
however a general absence of direct references to side
effects caused by AL.I: So, this malaria that we are talking about, did it
end with the drugs [AL] and come again or did it
never even with the drugs?
R3: For me, when I was taking the drug the malaria
was still with me.
R1: For me, when I finished taking the drugs the malaria
also stopped for some time before it came back.
R5: In my case, when I took the drug I was ok. I did
not have malaria again.
FGD, IST-arm participants (Yua CHPS)
In contrast, trial staff described trial participants com-
plaining about AL causing side effects, including nausea,
dizziness and appetite suppression. Complaints also cen-
tered on the perceived high number of tablets that a treat-
ment course of AL entailed (a total of 24 tablets over three
days). One woman was reportedly dissuaded from taking
AL by another health worker (who had no association with
the trial) who advised that AL was too ‘strong’ for use
during pregnancy and that it could lead to miscarriage.
R: [Trial participants] are complaining about the
Coartem [AL].
I: What are some of the complaints that they talk
about?
R: There are many. They say that to take four [tablets
per dose] is too much. They are complaining about the
number. They say that even taking one is not easy for
them. Some of them don’t eat well before they come [to
the health facility], so when they take the medicines
they feel like vomiting.
IDI, trial midwife
In spite of the concerns, trial staff were confident
about participants’ non-observed adherence to the AL
treatment course. Although the women took all but the
first dose of AL unobserved, on follow-up visits trial staff
collected the empty AL blisters. They based their asser-
tions about adherence on this and also on women’s posi-
tive reports of the efficacy of AL in terms of reducing
their symptoms of malaria. There was however one re-
port of non-adherence caused by AL-associated side ef-
fects: the trial field supervisor had visited a woman whose
experiences of dizziness had led her to stop taking the tab-
lets. Based on his advice about the malaria infection not
being cured, the participant restarted the AL course. An-
other woman described how she had taken the treatment
course over four days rather than three.
I: So for the Coartem [AL] they take all even if they
complain that they cannot eat well?
R: Yes, though they complain they still take it.
IDI, trial coordinator
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Trial participants complained directly of side effects as-
sociated with SP. These included vomiting, nausea, diar-
rhoea, appetite suppression or increase, general body
weakness, and dizziness. Based on their negative experi-
ences, some women questioned trial staff about the ben-
efits of such drugs, and were told that they prevented
malaria and were beneficial for both women and their
children. The side effects also varied across the IPTp-SP
doses and women did not necessarily experience side ef-
fects with every dose.
R1: It is the white large medicines [SP] that are very
difficult to take. When you take them you vomit all
the time and you also have body weakness and you
lose appetite.
[…]
R3: Yes, those three tablets [of SP] are really a
problem. When you take them and you get to the
house it is always like you are drunk…
R2: When I take them I become very weak and eat a
lot…I have never vomited after taking them.
I: Is there any of you here that the [SP] has no effect on?
R4: The first and second time that I took the big white
medicine, I did not have any problem but the third
time that I took it I vomited lots.
R5: When I took it for the first time and got to the house
it was like I had diarrhoea; the second time, the same
thing happened but with body weakness; and the third
time, when I got to the house after taking the medicine I
was a little dizzy but it was just for some short time.
I: And has anybody taken it and had no problem?
R6: I also had a problem when I took them it made feel
like vomiting but I could not vomit.
FGD, IPTp-arm participants (Kassena-Nankana East
Health Centre)
One trial staff member explained the frequency of SP-
related side effects in terms of the poverty and resultant
poor diets of pregnant women in the area.
You know, in this part of the country the poverty is high.
Some people do not eat until afternoon or so. So, when
pregnant women take the SP without food they become
dizzy. So we always tell them at least to take [flour and
water] with groundnuts before they take the drugs.
IDI, trial midwife
In light of the side effects, trial staff suggested that if
SP was not delivered under directly observed therapy
(DOT) conditions, women would discard the tablets.
However, the staff and even one trial participant recog-
nized the effectiveness of IPTp with SP in terms ofreducing the negative effects of MiP, particularly a
reduction in miscarriage and improvement in birth
weight.
I think the white [SP] tablets are very good because the
drug prevents the child from getting malaria. Now you
can see that when you give birth to your children they
look very strong. Before, many people were losing their
pregnancy because of malaria. But now there is
prevention.
FGD, participants from both trial arms (Sirigu CHPS)
IPTp and IST within a clinical trial
Trial participants’ attitudes towards the interventions
were inevitably influenced by the context in which they
were delivered. Participation in the clinical trial was gen-
erally popular, particularly because of the health care
and other benefits that were offered. Indeed, although
the trial enrolment criteria restricted participation to
women of parity two and below, health staff reported
that women of higher parity sought to enrol in the study,
citing the benefits, particularly an ITN (which were not
always provided free of charge at ANC) and requested
that staff ignored this exclusion criterion. The local re-
search institute, in collaboration with various overseas
partners, has conducted a range of clinical studies in the
area and trial participants generally valued these activ-
ities, again, particularly for the benefits that participants
received, which reportedly included lifts to and from
health facilities and food. Previous experiences of such
benefits, and anticipation that these would be provided,
also prompted women to participate in this particular
study. Benefits were however the same for participants
in both arms of the trial. Therefore they are likely to
have affected attitudes towards both interventions in a
similar manner.
Discussion
Several issues were particularly relevant to the accept-
ability of IST with AL and IPTp with SP in the context
of a clinical trial in Upper East, Ghana. These include
the response to the finger-prick blood sampling required
to perform malaria screening using an RDT and the atti-
tudes towards the anti-malarials, in terms of their ease
of use, perceived efficacy and side effects. Although the
data were collected in the context of a clinical trial, the
findings provide useful pointers for the possible future
implementation of IST (presumably replacing IPTp) as
part of standard ANC procedures. To offer some insights
for the potential implementation of IST, these findings are
discussed below with reference to the broader study on
the social and cultural context of MiP and other research
of which these data form a small part [18,20-22] and other
relevant research.
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Trial participants valued the opportunity to receive a
malaria diagnosis with an RDTand this reflected a broader
appreciation of malaria (and other) diagnostic technolo-
gies. In this regard, IST is potentially more appealing to
women than IPTp. Furthermore, in general, pregnant
women interviewed for the wider study on the social and
cultural context of MiP at this and other sites [18] viewed
diagnosis with an RDT (or laboratory test) positively. Posi-
tive attitudes towards RDTs (albeit for other populations
groups) have also been highlighted in southern and central
Ghana [27,28]: in both these studies, RDTs were viewed as
an indication of quality of care.
The value placed on malaria diagnostic tests must
however be viewed within the complex relationship be-
tween biomedically defined malaria, local illness con-
cepts that equate roughly with malaria and the ‘normal’
symptoms of pregnancy as previously described in Ghana
and elsewhere [22]. This relationship often entails a par-
tial overlap in terms of symptoms. Therefore a bout of
‘malaria’ (or the roughly equivalent local illness), which is
labelled according to an individual’s symptoms, may not
be diagnosed as biomedically defined malaria. Indeed,
for respondents in Upper East (and elsewhere), a positive
malaria test result was viewed as confirming an infec-
tion. However, a negative result was sometimes ques-
tioned and this potentially leads to doubts about the
accuracy of malaria tests.
A recent systematic review has highlighted a paucity of
research on RDT use during pregnancy [29] but studies of
RDT acceptability in other groups have been conducted.
Such research in Ghana also highlighted mixed conse-
quences of a negative test result [27,28]: for example, some
care providers of infants said that they would obtain an
ACT elsewhere if none were prescribed [28]. Therefore, to
maintain confidence in the RDTs – and particularly if their
use is expanded significantly as the implementation of IST
entails – it is important that health staff are aware of
relevant local illness concepts and their relationship with
biomedically defined malaria, and explain carefully the
implications of the result.
The wider programme of research on the social and
cultural context of MiP revealed that negative malaria
test results also led to uncertainty among Ghanaian
health staff [18]. Cases of pregnant women being treated
with anti-malarials in spite of a negative result were
identified. This resulted from a misinterpretation of
the relevant policy document, which states that, in the
absence of laboratory diagnosis, pregnant women with
clinical symptoms of malaria should not be denied anti-
malarials because the risk of not treating far outweighs
the risks associated with over-treatment [30].
Over-treatment of malaria is however not restricted to
pregnant women in Ghana. Research on malaria diagnosesacross Africa has revealed a lack of confidence in tests and
reliance on symptoms [31,32]. For example, in northern
Tanzania, over-treatment of malaria in general was linked
to a range of factors, including health care staff members’
assumptions about malaria being the most important dis-
ease and patients’ expectations [31]. Although training
can probably only go so far in terms of addressing the role
of malaria treatment in terms of health staff satisfying the
demands of their patients, were IST to be implemented, it
is clear that any accompanying training should emphasize
the importance of following case management guidelines.
A study in central Ghana on health staff ’s knowledge
of IPTp and case management during pregnancy re-
vealed their varied awareness of the relevant guidelines
[33]; almost 90% of health staff could describe all ele-
ments of the IPTp with SP policy, whereas 20 and 41%
could correctly explain malaria case management policy
in first or second/third trimesters, respectively. For these
study respondents, having participated in a workshop on
the IPTp policy strongly influenced whether they could
correctly describe the policy. So, although the lack of
knowledge about appropriate case management during
pregnancy does not bode well for the implementation of
IST, these results indicate that providing training can
lead to high levels of awareness of policy guidelines.
For some pregnant women, the benefits of accurate
diagnosis were also counterbalanced by the pain and dis-
comfort of a finger prick. Indeed, trial staff were pessim-
istic about women’s readiness to undergo finger prick,
but respondents were often willing to suffer the discom-
fort. Because of the additional benefits of participating in
the clinical trial it is difficult to extrapolate this particu-
lar finding to the potential implementation of IST within
ANC. However, from the broader study on the social
and cultural context of MiP, it was clear that generally
women trusted the advice of health staff and followed
their instructions [18]. Furthermore, findings from the
broader study, and research by Smith et al. [12] in cen-
tral Ghana, emphasize how women tend to accept ANC
as a package of services with relatively little attention to
particular interventions. Given the often-hierarchical na-
ture of interactions between pregnant women and health
staff in ANC [21] it is also likely that many women would
not refuse a finger prick for fear of reprimand or possible
future refusal of care. Nonetheless, the uncertainty about
the impact of finger pricks on ANC attendance highlights
the need for further research linked to the implementation
of IST as part of ‘normal’ANC.
The reports of women demanding compensation for
follow-up blood sampling are probably related to the
context in which these data were collected and have lit-
tle relevance for implementation within ANC; in such a
clinical trial, there is often a tendency to incentivize any
contribution to the study. For example, on clinic visits,
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ance’ along with sodas and soap. Although small, such
tokens set a precedent. They also signal a different bal-
ance of power in interactions with staff compared to that
commonly encountered in ‘normal’ health care interac-
tions; trial participants interpret their involvement as
valuable and therefore make assumptions about compen-
sation, whereas, in health facilities, help is sought and preg-
nant women (or any other group) are largely dependent
on the heath staff (and often fear reprimand by refusing
treatment).
Anti-malarials for treatment or prevention
Interviewed trial participants complained about the side
effects after taking SP for IPTp. This was also reflected
in the wider study on the social and cultural context of
MiP, which recorded complaints at every site (Central
and Upper East Ghana, Kenya and Malawi) [18]. How-
ever, it is noteworthy that the complaints were most vo-
ciferous in the Upper East Ghana site. In spite of the
complaints, across the sites reports of women not taking
their SP tablets were rare, even – despite the policy of
DOT – if they were given them to take at home or out-
side the consulting room. The cases of non-adherence
were linked to personal experiences of vomiting after
past doses. This was further indicative of women’s gen-
eral desire to follow the instructions of health staff even
though they experienced discomfort.
By contrast, the complaints about AL were indirect:
trial staff reported women’s objections to the number of
tablets that a treatment course entailed or the ‘strength’
of the anti-malarial. Nonetheless, trial staff were confident
that the women completed the treatment courses despite
these misgivings and, in this study, only one case of re-
ported partial adherence to the AL trial regimen was re-
ported by a trial participant. Nonetheless, given the use of
a multiple-dose treatment regimen and, particularly dur-
ing the possible roll-out, the absence of DOT for all but
the first dose, the questions about the impact of such con-
cerns on adherence are key for the success of IST.
Other research with non-pregnant participants has
highlighted mixed levels of adherence to AL: 90% prob-
ably adherent in southwest Uganda [34], compared to
65% in southern Malawi [35] and 38% in northern
Ethiopia [36]; whereas only 1.7% of over 500 respon-
dents missed a dose in rural Tanzania [37]. The range of
adherence results from the varied contexts in which the
research was conducted and the study designs (including
the definition of adherence) [36]. Informing participants
that they would receive a follow-up visit has however
been suggested to particularly improve adherence [36].
With regard to pregnant women, qualitative research
at the same site in northern Ghana identified four respon-
dents as having not completed their treatment course ofanti-malarials during pregnancy; side effects played a role,
as did confusion about the advice from health care staff,
particularly if it contradicted ideas about malaria causation
[18]. Meñaca et al. [16] also highlighted how, in Ghana,
MiP-related health messages tended to focus on the use
of non-prescribed and non-biomedical treatment during
pregnancy, with little emphasis on adherence to prescribed
anti-malarial regimens. To ensure the success of IST, re-
lated messages would have to emphasize the importance of
following dosage instructions and completing a treat-
ment course. Furthermore, appropriate health messa-
ging is particularly important in endemic areas where
MiP is often asymptomatic [1,38] as is research on AL
adherence among pregnant women.
Conclusion
Despite the discomfort of the finger prick required to per-
form the intermittent malaria screening, trial participants
generally expressed more positive sentiments towards IST-
AL than IPTp-SP. This was largely a result of the range and
severity of side effects directly associated with SP and the
value that they placed on malaria (and broader disease)
diagnosis. Nonetheless, questions remain about adherence
to a multiple-dose anti-malarial treatment regimen during
pregnancy, particularly in endemic areas where MiP is
often non-symptomatic. Further research in a non-clinical
trial context should address this issue. Any implementa-
tion of IST must be accompanied by appropriate health
messages on adherence and the necessary training for
health staff regarding case management guidelines.
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